D. E. Shaw & Co. Inc. raised its holdings in shares of Geron Co. (NASDAQ:GERN) by 1,211.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 248,803 shares of the biopharmaceutical company’s stock after purchasing an additional 229,827 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.13% of Geron worth $249,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also modified their holdings of GERN. SVA Plumb Wealth Management LLC lifted its holdings in Geron by 98.8% during the 4th quarter. SVA Plumb Wealth Management LLC now owns 50,300 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 25,000 shares during the last quarter. SG Americas Securities LLC lifted its holdings in Geron by 99.6% during the 4th quarter. SG Americas Securities LLC now owns 56,479 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 28,181 shares during the last quarter. Teachers Advisors LLC lifted its holdings in Geron by 11.2% during the 3rd quarter. Teachers Advisors LLC now owns 326,525 shares of the biopharmaceutical company’s stock worth $575,000 after buying an additional 32,948 shares during the last quarter. MetLife Investment Advisors LLC lifted its holdings in Geron by 50.1% during the 3rd quarter. MetLife Investment Advisors LLC now owns 117,168 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 39,095 shares during the last quarter. Finally, Paloma Partners Management Co bought a new position in Geron during the 3rd quarter worth approximately $100,000. Hedge funds and other institutional investors own 33.54% of the company’s stock.
A number of research analysts have commented on the company. Needham & Company LLC raised Geron from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a report on Tuesday, April 9th. BidaskClub downgraded Geron from a “buy” rating to a “hold” rating in a report on Tuesday. BTIG Research assumed coverage on Geron in a report on Tuesday, February 12th. They set a “buy” rating and a $4.00 target price on the stock. ValuEngine raised Geron from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, B. Riley raised Geron from a “neutral” rating to a “buy” rating and increased their target price for the stock from $1.50 to $3.25 in a report on Thursday, January 31st. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $3.31.
In related news, EVP Melissa Kelly Behrs sold 120,635 shares of the firm’s stock in a transaction that occurred on Tuesday, April 9th. The stock was sold at an average price of $2.00, for a total value of $241,270.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 8.20% of the company’s stock.
Shares of NASDAQ GERN opened at $1.79 on Wednesday. Geron Co. has a 12-month low of $0.95 and a 12-month high of $6.99.
Geron (NASDAQ:GERN) last announced its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The business had revenue of $0.38 million for the quarter, compared to the consensus estimate of $0.22 million. Geron had a negative return on equity of 17.61% and a negative net margin of 2,534.43%. On average, analysts predict that Geron Co. will post -0.34 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Geron Co. (GERN) Holdings Raised by D. E. Shaw & Co. Inc.” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thelincolnianonline.com/2019/04/17/geron-co-gern-holdings-raised-by-d-e-shaw-co-inc.html.
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.
Further Reading: The Discount Rate – What You Need to Know
Want to see what other hedge funds are holding GERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Geron Co. (NASDAQ:GERN).
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.